like to clarify a significance change of Group’s operation results were summarized as follows 1. Revenue from sales of goods and rendering of services for the year 2019 decreased by 13% compared to the
margin of land and houses in the Third Quarter 2020 and 2019 were 24.76 % and 25.02 % respectively, increased 0.0027 %. 4. Expenses 4.1 Selling expenses In the third quarter 2020, the selling expenses at
, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 2. Costs of sales and gross profit Costs of sales were Baht 117 .60 million in the first nine months of 2019, a surge of Baht 32 .42 million
equipments and with additional long-term investment. Total Current Liabilities were Baht 184.41 million an increase from Baht 96.84 million as of 31 December 2018, mostly due to an increase in account payables
this draw 3. Selling expenses Selling expenses in the 3rd quarter of 2019 were 51.70 million baht, an increase of 45.71 million baht or 763.11 percent from the same period last year, due to the network
gross profit in Q2/2020 and 1H/2020 were THB 79 million and THB 216 million, respectively, which decreased by 61% from Q2/2019 and 44% from 1H/2019, corresponding to the decrease in total sales. • Gross
. After 5G consumer service had been launched in 4Q20, the operators were focusing on providing superior 5G service quality and coverage to capture high value segment and uplift ARPU. 5G adoption during
) and product (Biodiesel) were stocked during 15-20 days in the 2nd quarter of 2021. Besides, the Company emphasis on efficiently control production yield. Subsidiaries realized net loss of 3.68 million
Company has assessed the impact from such delay in project completion. In relation to this project, there were unbilled contract revenue amounting to Baht 57 million, which the collectability are directly
as there were various promotions on credit card. Bank fees also rose during Commart sales (2) an increase in e-Marketplace fees due to sales promotion with e-Marketplace platform and the increase in